Business Wire

CIRIUM

16.1.2024 10:01:26 CET | Business Wire | Press release

Share
Indian Airports Dominate Cirium’s 2023 On-Time Performance Review

Two of the top five global airports for on-time performance hailed from India this year, in Cirium’s annual On-Time Performance Review.

Rajiv Gandhi International Airport came second in the global rankings with 84.42% of flights on time, and Kempegowda International Airport hot on its heels with 84.08% of flights on time, in third place.

There was also a top place finish in the medium airports category for another APAC airport, with Osaka International Airport who managed an impressive 90.71% of flights on time. There was a second-place finish in the small airports category for Chubu Centrair International Airport (NGO) with 90.17% of flights on time, just 0.12% behind the top spot.

It should also be noted that Indigo Airlines was achieved an impressive fourth place in punctuality for the Asia Pacific Airline category with 82.12% of its flights arriving on-time. While operating nearly 680,000 flights in 2023.

An on-time flight is defined as a flight that arrives within 15 minutes of the scheduled gate arrival. For an airport, it is defined as departing within 15 minutes of its scheduled departure.

Jeremy Bowen, CEO of Cirium, said: "Cirium’s annual On-Time Performance Review is a global assessment of the punctuality of all types of carriers and airports, as evidenced by the widespread representation of operations from each corner of the globe, in this year’s review. Indian airports performed particularly well, with podium finishes in the global and large airport categories, and there was further representation for the APAC region in the other two airport categories as well. I’d like to extend my congratulations to all the featured airlines and airports in this year’s review.”

Now in its 15th year, the Cirium On-Time Performance program continues to meticulously monitor global airline operational performance. Our extensive and unbiased data, derived from over 600 real-time information sources, is essential for industry stakeholders. Our data encompasses airlines, airports, global distribution systems, civil aviation authorities, and more, ensuring a comprehensive and neutral perspective.

Cirium is continuing to lead the way, worldwide, in monitoring aviation on-time performance in the New Year, as the industry adjusts to post-pandemic norms. The company’s data and analytics are designed to provide industry stakeholders with a neutral, third-party perspective, based on the widest and deepest pool of information collected and curated from more than 600 sources of real-time flight information.

These include the airlines themselves, airports, global distribution systems, positional data, civil aviation authorities, air navigation service providers, proprietary data partnerships and the internet. Cirium’s on-time performance data is backed by a completely independent board of advisors, comprised of industry experts with an unbiased view of the aviation sector. The board’s oversight ensures accuracy and proper representation of all the information the company presents.

The top performing global airports of 2023 were:

Airport

On time ranking

On time departure

Total flights

Minneapolis-St. Paul International Airport (MSP)

1

84.44%

289,817

Rajiv Gandhi International Airport (HYD)

2

84.42%

168,426

Kempegowda International Airport (BLR)

3

84.08%

237,461

El Dorado International Airport (BOG)

4

84.01%

292,486

Salt Lake City International Airport (SLC)

5

83.99%

226,705

The top Asia Pacific Airlines of 2023 were:

Airline

On time ranking

On time arrival

Total flights

All Nippon Airways (NH)

1

82.75%

302,279

Japan Airlines (JL)

2

82.58%

308,302

Thai AirAsia (FD)

3

82.52%

113,871

IndiGo (6E)

4

82.12%

678,446

Air New Zealand (NZ)

5

79.68%

175,876

The full 2023 On-Time Performance Review is available for download at Cirium.com/on-time-performance

About Cirium

Cirium is the world’s most trusted source of aviation analytics. Through powerful data and analytics, coupled with decades of industry experience, Cirium is enabling airlines, airports, travel companies, aircraft manufacturers, and financial institutions, amongst others, to make intelligent and informed decisions that improve operations, grow revenues, and enhance customer experiences.

Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or visit www.cirium.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116289335/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye